BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 29446543)

  • 1. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
    Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis.
    Zhang W; Kuang P; Liu T
    Ann Med; 2019 Feb; 51(1):28-40. PubMed ID: 30592434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
    Ribera J; Morgades M; Zamora L; Montesinos P; Gómez-Seguí I; Pratcorona M; Sarrà J; Guàrdia R; Nomdedeu J; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; González-Campos J; Barba P; Escoda L; Genescà E; Solé F; Millá F; Feliu E; Ribera JM;
    Cancer; 2015 Nov; 121(21):3809-17. PubMed ID: 26194343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.
    Iacobucci I; Ferrari A; Lonetti A; Papayannidis C; Paoloni F; Trino S; Storlazzi CT; Ottaviani E; Cattina F; Impera L; Abbenante MC; Vignetti M; Vitale A; Potenza L; Paolini S; Soverini S; Pane F; Luppi M; Foà R; Baccarani M; Martinelli G
    Clin Cancer Res; 2011 Dec; 17(23):7413-23. PubMed ID: 22134481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.
    Kathiravan M; Singh M; Bhatia P; Trehan A; Varma N; Sachdeva MS; Bansal D; Jain R; Naseem S
    Leuk Lymphoma; 2019 Feb; 60(2):433-441. PubMed ID: 29966470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
    Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
    Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic CDKN2A/2B deletions in adult Ph
    Pfeifer H; Raum K; Markovic S; Nowak V; Fey S; Obländer J; Pressler J; Böhm V; Brüggemann M; Wunderle L; Hüttmann A; Wäsch R; Beck J; Stelljes M; Viardot A; Lang F; Hoelzer D; Hofmann WK; Serve H; Weiss C; Goekbuget N; Ottmann OG; Nowak D
    Blood; 2018 Mar; 131(13):1464-1475. PubMed ID: 29348129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951.
    Mirebeau D; Acquaviva C; Suciu S; Bertin R; Dastugue N; Robert A; Boutard P; Méchinaud F; Plouvier E; Otten J; Vilmer E; Cavé H;
    Haematologica; 2006 Jul; 91(7):881-5. PubMed ID: 16818274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
    Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
    Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
    Kim M; Yim SH; Cho NS; Kang SH; Ko DH; Oh B; Kim TY; Min HJ; She CJ; Kang HJ; Shin HY; Ahn HS; Yoon SS; Kim BK; Shin HR; Han KS; Cho HI; Lee DS
    Cancer Genet Cytogenet; 2009 Nov; 195(1):59-65. PubMed ID: 19837270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biallelic loss of CDKN2A is associated with poor response to treatment in pediatric acute lymphoblastic leukemia.
    Braun M; Pastorczak A; Fendler W; Madzio J; Tomasik B; Taha J; Bielska M; Sedek L; Szczepanski T; Matysiak M; Derwich K; Lejman M; Kowalczyk J; Kazanowska B; Badowska W; Styczynski J; Irga-Jaworska N; Trelinska J; Zalewska-Szewczyk B; Pierlejewski F; Wlodarska I; Młynarski W;
    Leuk Lymphoma; 2017 May; 58(5):1162-1171. PubMed ID: 27756164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.
    Genescà E; Lazarenkov A; Morgades M; Berbis G; Ruíz-Xivillé N; Gómez-Marzo P; Ribera J; Juncà J; González-Pérez A; Mercadal S; Guardia R; Artola MT; Moreno MJ; Martínez-López J; Zamora L; Barba P; Gil C; Tormo M; Cladera A; Novo A; Pratcorona M; Nomdedeu J; González-Campos J; Almeida M; Cervera J; Montesinos P; Batlle M; Vives S; Esteve J; Feliu E; Solé F; Orfao A; Ribera JM
    J Hematol Oncol; 2018 Jul; 11(1):96. PubMed ID: 30041662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia.
    Jang W; Park J; Kwon A; Choi H; Kim J; Lee GD; Han E; Jekarl DW; Chae H; Han K; Yoon JH; Lee S; Chung NG; Cho B; Kim M; Kim Y
    Exp Mol Med; 2019 Jan; 51(1):1-15. PubMed ID: 30635552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
    J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Yin and Yang-Like Clinical Implications of the
    González-Gil C; Ribera J; Ribera JM; Genescà E
    Genes (Basel); 2021 Jan; 12(1):. PubMed ID: 33435487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion analysis of p16(INKa) and p15(INKb) in relapsed childhood acute lymphoblastic leukemia.
    Graf Einsiedel H; Taube T; Hartmann R; Wellmann S; Seifert G; Henze G; Seeger K
    Blood; 2002 Jun; 99(12):4629-31. PubMed ID: 12036898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia.
    Carrasco Salas P; Fernández L; Vela M; Bueno D; González B; Valentín J; Lapunzina P; Pérez-Martínez A
    Pediatr Hematol Oncol; 2016; 33(7-8):415-422. PubMed ID: 27960642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
    Ribera J; Zamora L; Morgades M; Vives S; Granada I; Montesinos P; Gómez-Seguí I; Mercadal S; Guàrdia R; Nomdedeu J; Pratcorona M; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; Ciudad J; Orfao A; González-Campos J; Barba P; Escoda L; Esteve J; Genescà E; Solé F; Feliu E; Ribera JM; ;
    Genes Chromosomes Cancer; 2019 Nov; 58(11):815-819. PubMed ID: 31340073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia.
    Zhou M; Gu L; Yeager AM; Findley HW
    Pediatr Hematol Oncol; 1997; 14(2):141-50. PubMed ID: 9089742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias.
    Iolascon A; Faienza MF; Coppola B; della Ragione F; Schettini F; Biondi A
    Leukemia; 1996 Feb; 10(2):255-60. PubMed ID: 8637234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.